Amarin Corp Plc (AMRN)

[lizzy241]

For those who follow HLS please see below,

Q2 & YEAR-TO-DATE ("YTD") 2023 FINANCIAL & OPERATIONAL HIGHLIGHTS
• Q2 2023 Vascepa net revenue was C$4.5 million, up 49% compared to C$3.0 million in Q2 2022.
• Vascepa total prescriptions in Q2 2023 increased by 91% year-over-year from Q2 2022.
• Vascepa prescribers in Q2 2023 increased by 20% sequentially from Q1 2023 and 96% year-over-year from Q2 2022.
• Vascepa consistent prescribers2 in Q2 2023 increased by 30% sequentially from Q1 2023 and 139% year-over-year from Q2 2022.
• Clozaril YTD 2023 Canadian net revenue was C$17.1 million, down 1.5% compared to C$17.3 million in the same period last year.
• Clozaril's YTD 2023 patient growth rate was 1%.
"Vascepa generated 49% year-over-year net sales growth in Q2 with 91% growth in prescribing driven by increases in new prescribers, new patients, and more prescribing by current writers," Millian added. "We are excited about the continued adoption of Vascepa and opportunities for future growth, while also acknowledging that the current growth trajectory is not as rapid as originally projected. Our goal moving forward is to invest where we can drive continued growth but with an accelerated timeframe to brand profitability."
Due to payer mix dynamics, public plan reimbursement delays, and slower than expected uptake with general practitioners, HLS is guiding to a 2023 Vascepa revenue range of C$18-20 million compared to the low end of its previously issued C$22-28 million revenue range. The Company remains confident in the potential for Vascepa and is putting plans in place so that Vascepa begins to make a positive contribution to Adjusted EBITDA in the second half of 2024.